医学
肿瘤科
内科学
肺癌
突变体
药品
完全响应
总体生存率
最大耐受剂量
癌症
胃肠病学
药理学
化疗
生物
生物化学
基因
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2022-06-06
卷期号:12 (8): OF1-OF1
被引量:3
标识
DOI:10.1158/2159-8290.cd-nb2022-0042
摘要
In the phase II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib yielded an overall response rate of 43% and a disease control rate of 80% in patients with previously treated KRASG12C-mutant non-small cell lung cancer. After a median follow up of 12.9 months, overall survival was 11.7 months. The drug also shrank brain metastases in 33% of patients who had them.
科研通智能强力驱动
Strongly Powered by AbleSci AI